Compare Microsoft (MSFT) vs TG Therapeutics Inc (TGTX) Price & Performance

Microsoft (MSFT) trades at $493.21, down 2.54% in the last session, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $4.74 surpassing the $4.24 estimate. Revenue grew to $281.72 billion in 2025, supported by a net income margin of 40.31% and robust cash flow from operations of $136.16 billion. Recent news highlights AI leadership and Azure momentum, though capital expenditure concerns persist.

Outlook remains positive with an 80.49% analyst buy rating and a $555 consensus price target, implying over 12% upside. Risks include competitive pressures in AI, high valuation multiples like a P/E of 28.07, and macroeconomic volatility. The stock's fundamentals and institutional support suggest long-term growth potential, but investors should monitor execution on AI investments and spending trends.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.